STOCK TITAN

Xenon Pharmaceuticals Inc - XENE STOCK NEWS

Welcome to our dedicated news page for Xenon Pharmaceuticals (Ticker: XENE), a resource for investors and traders seeking the latest updates and insights on Xenon Pharmaceuticals.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Xenon Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Xenon Pharmaceuticals's position in the market.

Rhea-AI Summary
Xenon Pharmaceuticals Inc. to host investor webinar on major depressive disorder, featuring key opinion leaders. Webinar will take place on September 19, 2023, from 11:30 am to 1 pm ET. Participants can register on Xenon's website. Live webcast will be available on the Investors section of the website and replay will be posted later.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.83%
Tags
conferences
-
Rhea-AI Summary
Xenon Pharmaceuticals presents positive interim data from Phase 2b X-TOLE trial at IEC 2023, demonstrating improvement in quality-of-life for epilepsy patients. Seizure reduction and improvements seen across important subscales. XEN1101 shows promise as a potential treatment for epilepsy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Xenon Pharmaceuticals to present at Wells Fargo 2023 Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.92%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.29%
Tags
-
Rhea-AI Summary
Xenon Pharmaceuticals (XENE) appoints Dr. Gillian M. Cannon and Mr. Justin Gover to its Board of Directors, bringing extensive experience in the pharmaceutical and biotechnology industries, with a focus on neurology and epilepsy. Dr. Cannon has over 30 years of experience in business and commercial leadership roles at Merck, UCB, Otsuka, and Roivant, while Mr. Gover served as the founding CEO of GW Pharmaceuticals and brings nearly twenty-five years of industry experience. Xenon is preparing for the commercialization of XEN1101 and nearing a topline readout of its X-NOVA clinical trial in major depressive disorder.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.28%
Tags
management
-
Rhea-AI Summary
Xenon Pharmaceuticals to report Q2 2023 financial results on August 9, 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.4%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.12%
Tags
conferences
-
Rhea-AI Summary
Xenon Pharmaceuticals Inc. will present at the 2023 Jefferies Healthcare Conference on June 7th. The presentation will be given by the President and CEO, Ian Mortimer, and CFO, Sherry Aulin.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.31%
Tags
conferences
-
Rhea-AI Summary
Xenon Pharmaceuticals Inc. to present at the 2023 RBC Capital Markets Global Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.02%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.51%
Tags
Xenon Pharmaceuticals Inc

Nasdaq:XENE

XENE Rankings

XENE Stock Data

3.12B
69.56M
0.38%
99.99%
3.65%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
Canada
Burnaby

About XENE

xenon® (nasdaq: xene) is a biopharmaceutical company focused on the development of novel medicines through the application of our proprietary discovery platform, which we refer to as extreme genetics. our product candidates are based on genetic insights derived from our research of families where individuals exhibit severe traits, or phenotypes. we apply our expertise to predict which phenotypes are caused by single-gene defects. by identifying and characterizing the single-gene defects responsible for such severe phenotypes, we gain valuable insights into their function in human biology and their potential as drug targets. given that these targets are often involved in diseases beyond the rare genetic disorders in which they are first identified, we are developing proprietary product candidates to treat both orphan as well as more prevalent diseases.